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ABSTRACT
Objective: Oral contraceptives are the second-most widely used contraceptives in Indonesia; however, a high percentage rate of withdrawal is seen 
owing to adverse drug reactions (ADRs). Only a small proportion of users have been provided information about other oral contraceptives such as 
newer generation progestin as an alternative option to minimize ADR. This study aimed to compare the prevalence of ADR between combined oral 
contraceptives containing levonorgestrel (LNG) (second generation) and desogestrel (DSG) (third generation), which was expected to have less side 
effects.
Methods: The study has a cross-sectional comparative design with random sampling from users in six villages in Depok City, Indonesia. Data were 
collected through interviews. The sample includes 60 users of LNG and 40 users of DSG.
Results: ADR complaints include intermenstrual bleeding (16.7% vs. 5%), headache (16.7% vs. 5%), nausea/vomiting (25% vs. 0%), breast tenderness 
(13.3% vs. 0%), impaired sexual intercourse (23.3% vs. 7.5%), weight gain (35% vs. 22.5%), acne (3.3% vs. 7.5%), and face spots/chloasma (28.3% 
vs. 5%). The LNG group showed significantly higher impaired sexual intercourse (odds ratio (OR): 3.75, 95% confidence interval (CI): 1.003-14.050, 
p=0.039) and chloasma (OR 7.51, 95% CI: 1.629-34.647, p=0.004).
Conclusion: Users’ low knowledge of ADR and how to treat it could be a reason for drug withdrawal. Pharmacies must make efforts to provide 
counseling in this regard.
Keywords: Oral contraceptive, Levonorgestrel, Desogestrel, Adverse drug reaction.
INTRODUCTION
Hormonal contraception poses a risk of adverse drug reactions (ADRs); 
this may result in reduced patient compliance and, in turn, reduced 
effectiveness of contraception [1]. Combined oral contraceptives are the 
second most frequently used hormonal contraception method (13.6%) 
in Indonesia after injections (32%) [2]. Oral contraception methods are 
short-term in nature. Their effectiveness strongly depends on patient 
compliance and the continuity of the acceptor [3]. However, evaluations 
have shown that withdrawal from the use of oral contraceptives due 
owing to ADR is quite high (13.2% in the 1st year and 14.9% in the 
5th year). ADR is the second most frequent cause of contraception 
withdrawal after the desire to have another child [2].
Studies have shown that the use of second-generation combined oral 
contraceptives has a higher withdrawal rate than that of third-generation 
ones because of their side effect such as menstruation cycle disturbance 
[4]. Second-generation combined oral contraceptives available in 
Indonesia include pills containing progestin levonorgestrel (LNG), and 
third-generation contraceptives include pills containing drospirenone, 
gestodene, and desogestrel (DSG). Other studies have shown that third-
generation combined oral contraceptive users (24%) tend to complain 
more about headaches compared to second-generation users (5.8%) 
[5]. ADR manifestations are influenced by many factors including race, 
dosage, duration of drug use, medical history, and patient lifestyle [1]. The 
differences in the effects of DSG and LNG may be caused by differences 
in substance affinity with hormone receptors and different androgenic 
effects [6]. DSG is a third-generation combined oral contraceptive that has 
a smaller androgenic effect compared to LNG. Therefore, ADR complaints 
caused by androgenic effects such as acne and lipid level increase are 
expected to be smaller with DSG than with LNG [7].
Relatively, few users are informed of ADR and steps to take when 
ADR occurs (27.8% and 23.9%, respectively). In most cases (68.2%), 
Indonesia users of oral contraceptives obtain them from private sector 
providers such as midwives, pharmacies, and clinics; however, they 
do not have adequate information on ADR. This lack of knowledge 
influences their decision to prematurely withdraw from pills [2]. 
Data from the national population and family planning commission 
shows that Depok city has a high number of oral contraceptive users. 
Thus, the researcher chose Sukmajaya, a location in Depok city, as the 
research location. This research compares the use of ethinyl estradiol 
(EE)-LNG and (EE-DSG), difference in ADR between both groups, 
and contribution of contraceptive use to ADR. The study results will 
hopefully increase contraception services and support preventative 
and treatment programs for contraceptive-related ADR. In addition, the 
study is expected to be useful for the development of tracking methods 
of ADR incidence, especially the contraceptive-related ones.
METHODS
Research Article
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This study used an observational cross-sectional approach. It 
was conducted in all subdistricts of Sukmajaya, Depok city, namely, 
Mekar jaya, Sukmajaya, Abadi Jaya, Bakti Jaya, Cisalak, and Tirta
 Jaya. The necessary permission was obtained from the district 
and sub district officials. Data were obtained with the help of 
family planning field officers in each sub district. A random 
sample was obtained from these records. The study purpose 
was explained to these subjects, and informed consent was 
obtained from them for participating in the study. The subjects 
were divided into two groups: EE-LNG and EE-DSG oral 
contraceptive users. Subjects in the EE-LNG group used a 
contraceptive containing 30 µg of EE and 150 µg of LNG. Subjects in the 
EE-DSG group used a contraceptive containing 30 µg of EE and 150 µg
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of DSG. Up to 10 subjects/group/sub district were randomly selected 
from each population group. However, each district generally had <10 
EE-DSG users, so total sampling was performed to satisfy the minimum 
sample size (39 people). A total sample of 100 subjects participated in 
this study, with 60 and 40 subjects in the EE-LNG and EE-DSG groups, 
respectively.
The ADRs evaluated in this study include intermenstrual bleeding, 
headaches, breast tenderness, nausea/vomiting, weight gain, impaired 
sexual intercourse, and acne. The researcher classified headache, 
breast tenderness, nausea/vomiting, impaired sexual intercourse, and 
acne as ADR if there was an increase in their frequency after the use of 
contraceptives. Weight gain was reported as a subjective assumption by 
users because of the lack of monitoring data of users before they started 
using contraceptives. Data are obtained through an by interview base 
on using a questionnaire written by the author. The questionnaire was 
tested for validity and reliability by 30 lay women who were not part of 
the study sample. The questionnaire consisted of 41 questions, of which 
29 were related to ADR complaints. The validity tests showed that the 
first five questions related to ADR had r<0.361. This error is related to 
a structural error, and the author altered the diction used so that it can 
be interpreted easily; furthermore, the author altered the order of the 
answers to avoid errors in the codes given by the subjects. Ultimately, 
all questions were valid with Cronbach’s α>0.7. Univariate and bivariate 
data analysis were conducted using a statistical software. The bivariate 
analysis included Chi-square and Fisher exact tests, odds ratio (OR), 
and correlation analysis. The confidence interval (CI) used was 95% 
with a test power of 80%.
RESULTS
The data from contraceptive users in Sukmajaya indicated that oral 
contraceptives were the second most frequently used contraception 
method (29.38%) after injection method (33.27%) (Table 1). Both groups 
showed similar sociodemographic characteristics. Most respondent 
were ≥35 years old (76%), unemployed (91%), married for 5-20 years 
(55%), had <3 children (70%), and educated until high school/similar 
level (74%). In terms of body mass index (BMI), respondents were 
mostly normal (51%) or overweight (41%). In terms of duration of 
contraceptive use, 83% of respondents used oral contraceptives for 
>6 months; 12%, for 3-6 months; and 5%, for <3 months. Respondents 
mainly chose oral contraceptives because of their practicality (26%), 
safety (13%), and ease of returning to a fertile state (3%). Five subjects 
from the EE-LNG group claimed economic reasons. Some subjects 
preferred it for regular menstruation (20%) because most of them 
previously used a 3-month depot medroxyprogesterone acetate (DMPA) 
injection that may cause amenorrhea [1]. Suggestions from midwives/
relatives were claimed as reasons by 20% of respondents.
Both groups claimed that they obtained their oral contraceptives from 
a pharmacy (78%) or midwive private practices (18%). Two subjects 
in the EE-LNG group obtained oral contraceptives from the community 
health center and 2 others, from a doctor’s practice. Of all respondents, 
31% said that they did not receive any information when purchasing 
oral contraceptives; the remaining 69% who received information 
said that they were only told of how to use the contraceptives. Only 6 
subjects in the EE-LNG group received information on the possibility 
of ADR. Furthermore, 83% of EE-LNG respondents and all EE-DSG 
respondents could correctly explain how to use oral contraceptives. 
Moreover, 43% of all respondents claimed to not know any side effects 
of the oral contraceptive they were currently using, whereas most 
respondents could name at least one side effect. Respondents mainly 
complained of side effects such as headache (32%), nausea (26%), and 
face spots (24%).
Of all respondents, 90% had used contraception methods other than 
combined oral contraception. The 3-month DMPA injection method 
was used most frequently before oral contraceptives (37.5%). 
Respondents’ reasons for switching methods included side effects 
(42%) and the desire to have another child (2.5%). In the EE-DSG 
group, 90% of respondents did not have any restrictions for use 
(Category 1). In the EE-LNG group, 15% of respondents theoretically 
had a higher risk than benefit (Category 3), mainly because of 
hyperlipidemia or hypertension.
Both groups complained of 6 out of 8 ADRs that were analyzed. The 
EE-DSG group did not report nausea and breast tenderness. In both 
groups, only impaired sexual intercourse and face spots showed 
statistically significant (p<0.05) results. Table 2 summarizes the 
respondents’ proportions of ADR.
DISCUSSION
The respondent profiles obtained in this study are in accordance 
with those of oral contraceptive users in Indonesia. A survey of the 
national population and family planning federation commission in 
2012 showed that oral contraceptive users in Indonesia are commonly 
from rural areas and ≥35 years old (53.7%) and that they obtain their 
contraceptives from a pharmacy (39.4%). Only 0.2% of users obtained 
their oral contraceptives from a community health center. Most users 
had more than three children [2].
Of all EE-DSG respondents, 27.5% claimed to choose the contraceptive 
because of advice from their midwife or relative, whereas most 
EE-LNG respondents claimed these reasons. This shows that advice 
from midwives and relatives plays an important role in respondents’ 
decisions to choose contraception methods. Most users obtained 
oral contraceptives from the pharmacy (78%), whereas only a small 
proportion (18%) obtained them from a midwife. EE-DSG pills were more 
expensive (Rp. 56,815) compared to EE-LNG ones (Rp. 8,000-10,000) 
(MIMS, 2015). None of the EE-DSG respondents chose cost as a reason 
for their choice, whereas 8.3% of EE-LNG respondents did. This is why 
there were lesser EE-DSG respondents in Sukmajaya than EE-LNG 
ones. Of all EE-LNG respondents, 50 (83%) could correctly explain 
how to use the contraceptive another 7 said that it should be taken 
in the morning, although it is suggested to take it at night [8]. Finally, 
Table 1: Respondents’ eligibility category for using combined oral contraceptives
Category Quantity (%) Annotation
EE-LVG group
1 (no restrictions for use) 45 (75)
2 (benefit is higher than risk) 5 (8.3) 4 subjects were breastfeeding (6.7%), 1 subject was obese (1.7%)
3 (theoretically, risk is higher than benefit) 10 (15) 2 subjects had controlled hypertension (3.3%), 4 subjects had 
hyperlipidemia (6.7%), 1 subject had controlled hypertension and 
hyperlipidemia (1.7%), 1 subject was obese and had hyperlipidemia (1.7%), 
1 subject was obese and had controlled hypertension (1.7%)
EE-DSG group
1 (no restrictions in use) 36 (90)
2 (benefit is higher than risk) 1 (2.5) Obesity
3 (theoretically, risk is higher than benefit) 3 (7.5) Controlled hypertension
LNG: Levonorgestrel, EE: Ethinyl estradiol, DSG: Desogestrel
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10 said that it need not be taken when menstruating. This is considered 
imprecise understanding because the contraceptives should be taken 
even when menstruating [8]. During menstruation, users commonly 
take a placebo pill, but they should continue to consume their pills 
during menstruation every month [9]. All EE-DSG respondents could 
correctly explain how to use the oral contraceptives. They noted that 
the pills were to be taken daily at night. Furthermore, they knew that 
if a pill was not taken on time, it should be taken as soon as possible; 
alternatively, two pills should be taken the next day [10]. This is owing 
to the information given to them by health caregivers. Information on 
ADR was given to only 10% of EE-LNG respondents and none of the 
EE-DSG respondents. This shows that information on contraception is 
not focused on risks. As with other hormonal contraception methods, 
oral contraceptives pose ADR risks that users must be aware of [3]. 
If adequate information about ADR and how to treat it is not given to 
users, it may lead to drug withdrawal or noncompliance [2].
Intermenstrual bleeding
Intermenstrual bleeding usually occurs in respondents who are 
≥35 years, have at most two children, and have normal BMI. This 
complaint is usually found in respondents who have used oral 
contraceptives for >6 months. Intermenstrual bleeding in combined 
oral contraceptive users may be influenced by the EE dosage; progestin 
preparate used EE:progestin ratio, user compliance, and history of 
cervical or pelvic diseases [11]. If users take the oral contraceptive 
regularly, interim bleeding usually only occurs in the first 3 months of 
use. However, if users are not compliant in taking the pills, they may 
experience intermenstrual bleeding after 3 months [12].
Of all respondents, 16.7% (10) in the EE-LNG group and 5% (2) 
in the EE-DSG group complained of intermenstrual bleeding. 
Theoretically, when used correctly, oral contraceptives do not cause 
intermenstrual bleeding. However, hormone fluctuations caused 
by user noncompliance may cause intermenstrual bleeding [13]. 
Smoking may also cause menstrual disturbances as it induces ethinyl 
estradiol metabolism [3]. None of the patients admitted to smoking; 
however, the bias of social judgement in admitting to smoking 
cannot be ignored. Oral contraceptives may also reduce the intensity 
of menstrual bleeding as well as the incidence and severity of 
dysmenorrhea. This is because EE influences the stability of the 
endometrial lining [14]. Data show that a decrease in menstrual 
bleeding intensity and/or duration occurs in 33.3% of EE-LNG 
respondents and 22.5% of EE-DSG respondents.
There are no statistically significant differences (p=0.117) in 
intermenstrual bleeding between both groups. The incidence of 
intermenstrual bleeding is higher in the EE-LNG group than in the 
EE-DSG group. These findings agree with Maitra et al.’s literature 
review [5]. Intermenstrual bleeding occurred in 43% of LNG users 
compared to 19.8% of DSG users [5]. It is concluded that both oral 
contraceptive pills pose intermenstrual bleeding risks, with a higher 
incidence rate in LNG users. Compliance in taking the oral contraceptives 
may mitigate this risk [13].
Headache
Complaints of headache in oral contraceptive users may be influenced 
by many mechanisms. One mechanism is a decrease in estrogen. 
Headaches are caused by low estrogen when users consume placebo 
pills during menstruation. Another mechanism is an increase in 
estrogen; this produces headaches when the contraceptives are 
taken. The incidence of such headaches decreases after multiple 
uses of the oral contraceptive [15]. Headaches were reported by 
10 (16.7%) EE-LNG respondents and 2 (5%) EE-DSG respondents; this 
difference was not statistically significant. Of all respondents, 33.3% 
experienced headaches when approaching menstruation and 41.67% 
experienced headaches moments after taking the pill. In the EE-DSG 
group, complaints of headaches only occurred when approaching 
menstruation, indicating that they were caused by a decrease in EE. In 
the EE-LNG group, headaches were caused more often after taking the 
pill (50%) rather than when approaching menstruation (20%). These 
differences are influenced by the respondents’ sensitivity to EE and the 
risk of LNG causing headaches [16]. This study shows that headaches 
occur more commonly in respondents ≥35 years; this findings are 
supported by Grossman Barr study [1]. Respondents complaining of 
headaches in this study had mostly been taking oral contraceptives for 
over 6 months (66.7%); it is hoped that the incidence would decrease 
after 6 months of use [17]. The low incidence of headaches in the EE-DSG 
group was caused by DSG, which has a positive effect on headache 
frequency. Merki-Feld et al.’s study showed that 60% of participants 
experienced decreased headache incidence, frequency and intensity 
and need of medication when using pills containing only DSG [18]. This 
contradicts the findings of another study that showed that combined 
DSG pills have a higher headache incidence rate compared to LNG pills 
(24% vs. 5.8%) [4]. This may be caused by the difference in assessment 
methods and subject bias. In this study, the headache intensity was 
assessed using the Wong-Baker FACES pain rating scale. In general, both 
groups categorized their headaches as mild pain (60% of EE-LNG group 
vs. 100% of EE-DSG group). The questionnaire did not contain any 
questions about comparing headaches before and after contraceptive 
use, so whether contraceptive use causes more severe headaches 
remains unknown. Oral contraceptives are safe to use for users with 
headache complaints. Use should be avoided if users have stroke risk 
factors. When the headache intensity or frequency increases, other 
nonhormonal contraception methods should be considered. Users who 
experience headaches when approaching menstruation can instead use 
oral contraceptives with a shorter hormone-free interval [16].
Brest tenderness
As many as 8 (13.3%) EE-LNG respondents complained of breast 
tenderness after the use of contraceptives. These respondents 
were generally >35 years old, had normal BMI, and had used oral 
contraceptives for >6 months. Another 37.5% of respondents 
complained of breast tenderness when approaching menstruation, 
and others were not specific. No EE-DSG respondents complained of 
breast tenderness. This finding differs from that of a previous study 
that showed that the incidence of breast tenderness with the use of 
LNG and DSG was 4% and 8%, respectively [4]. As with headaches, 
Table 2: Respondents’ proportion of ADR with combined oral contraceptives in EE‑LNG and EE‑DSG groups, Sukmajaya 
District, Depok city, 2015
ADR n (%) OR (95% CI) (LNG/DSG) Significance
EE‑LNG EE‑DSG
Menstruation disturbance 10 (16.7) 2 (5) 3.8 (0.786-18.369) 0.117
Headache 10 (16.7) 2 (5) 3.8 (0.786-18.369) 0.117
Breast tenderness 8 (13.3) 0 - -
Nausea/vomiting 15 (25) 0 - -
Weight gain 21 (35) 9 (22.5) 1.855 (0.745-4.618) 0.181
Impaired sexual intercourse 14 (23.3) 3 (7.5) 3.754 (1.003-14.050) 0.039
Acne 2 (3.3) 3 (7.5) 0.425 (0.068-2.667) 0.386
Face spots 17 (28.3) 2 (5) 7.512 (1.629-34.647) 0.004
LNG: Levonorgestrel, EE: Ethinyl estradiol, DSG: Desogestrel, ADR: Adverse drug reaction, OR: Odds ratio, CI: Confidence interval
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breast tenderness can be associated with estrogen increase before 
menstruation [16]. Estrogen may cause node swelling in breast milk 
channels that traps fluid inside the breast and causes tenderness [1]. 
Breast tenderness may also occur after months of use [1]. Many other 
factors may contribute to breast tenderness, such as the use of an ill-
fitting bra and caffeine consumption [11].
Nausea/vomiting
No EE-DSG respondents experienced nausea after the use of 
contraceptives, whereas 15% of EE-LNG respondents did. This finding 
differs from that of previous studies that showed that the DSG group 
had higher nausea rate than the levonorgestrel group (12% vs. 4%) [4]. 
Nausea related to the use of oral contraceptives is caused by a decrease 
in the lower esophageal sphincter pressure or because of the inducing 
effect of the chemoreceptor trigger zone caused by the binding of the 
pills with the receptor in the digestive tract. Both effects might be 
caused by EE and/or its combination with different progestins [19]. 
High doses of progesterone can reduce the colon motility, resulting 
in an increase in the stomach clearance time [20]. This increases 
the risk of nausea/vomiting in oral contraceptive users [21]. The 
significant difference in both groups is caused by the sensitivity levels 
of respondents’ digestive tracts. Nausea can be reduced by taking the 
contraceptive at night [14].
Weight gain
There was statistically significant difference (p=0.181) in weight gain 
between both groups. Some studies also showed no significant difference 
in weight gain with the use of combined oral contraceptives [1]. 
Reviews also showed that the incidence rate of weight gain in DSG 
and LNG groups was similar (2% vs. 2.3%) [4]. Progestin has a large 
androgenic effect and is associated with appetite increase. Androgenic 
effects also increase the risk of abdominal obesity. Second-generation 
LNG is known to have a higher androgenic effect than DSG [22]. In this 
study, 35% of EE-LNG respondents and 22.5% of EE-DSG respondents 
experienced weight gain after using oral contraceptives. Weight 
gain was not accompanied by an increase in eating frequency. Only 
26.7% of respondents admitted to increased eating frequency owing 
to appetite increase (20%) and mood changes (13.3%). The average 
weight gain in respondents cannot be calculated as there is a lack of 
data on weight before starting the use of oral contraceptives. Unlike 
injection contraceptive users who are periodically tested for blood 
pressure and weight gain, oral contraceptive users are not supervised. 
It is recommended that weight and BMI be measured periodically in 
oral contraceptive users [11]. In this study, weight gain incidence was 
determined based on user complaints. The results showed no difference 
between the effects of second- and third-generation progestin on 
weight. Risk factors that may contribute to weight gain are BMI before 
the use of oral contraceptives and race [23]. This study did not obtain 
the BMI before the use of oral contraceptives, and all subjects were 
Asian.
Impaired sexual intercourse
In total, only 17% of respondents experienced impaired sexual 
intercourse; this included 23.3% (14) of EE-LNG respondents and 
7.5% (3) of EE-DSG respondents. This complaint was mainly caused by 
mood swings (52.9%) and pain/dryness during intercourse (29.4%). 
These complaints are, respectively, associated with the effect of EE 
on mood and that of progestin on genital dryness, which causes pain 
during intercourse [24,25]. Another study found that genital dryness 
occurs in 12.7% of respondents during the 3 months of EE-LNG use. 
Reduced sexual appetite occurs in 42.5% of respondents and reduced 
sexual satisfaction, in 37.2% of respondents. These complaints lessen 
as the duration of contraceptive use increases, although their incidence 
remains around 30% (14). One study found that oral contraceptive 
users who complain of impaired sexual intercourse are usually younger 
(<29 years), have higher education, and are Caucasians or South Asians. 
The study found that sexual complaints were related to the difference 
in each respondent’s preferential outcome. Younger women generally 
had higher expectations with regard to sexual intercourse [24,25]. 
This study had different findings, where complaints of impaired sexual 
intercourse were mostly experienced by women ≥35 years and with 
<3 children. Each respondent’s sexual expectation influenced the 
results. Mood swings that affect sexual intercourse may be caused by 
multiple factors. Only 5 respondents reported vaginal dryness. The 
EE-LNG group reported higher incidences of these complaints, and the 
difference between both groups was statistically significant (p=0.039). 
This suggests that EE-LNG is more likely to cause mood swings and 
vaginal dryness compared to EE-DSG. These findings are consistent with 
those of previous studies that state that third-generation contraceptive 
pills have better effects on women’s mood swings compared to second-
generation ones [26].
Acne
Only 3.3% of respondents in the EE-LNG group and 7.5% of respondents 
in the EE-DSG group experienced acne. The difference between the two 
groups was not statistically significant (p=0.386). In all respondents, 
60% of acne occurred when approaching menstruation and 40% was 
unspecified. This finding do not prove that DSG has less androgenic 
effects than LNG. Theoretically, the androgenic effect of DSG is smaller, 
and it is less likely to cause acne [6]. Previous studies have shown that 
DSG users experienced up to 70% improvement in acne [1]. Acne can 
also be influenced by the respondents’ sanitary habits [12]. This factor 
was difficult to evaluate in this study, so a conclusion cannot be made.
Face spots (chloasma)
The EE-LNG group (28.3%) showed a higher occurrence of chloasma 
than the EE-DSG group (5%), and the difference between the two 
groups was statistically significant (p=0.004). Chloasma is experienced 
by respondents ≥35 years and who have used oral contraceptives 
for >6 months. This finding is similar to that of other studies that 
showed that chloasma is more common in oral contraceptive users 
who have used these contraceptives for >10 years [27]. Other studies 
also support the findings that 25% of chloasma occurs after the use 
of contraceptives [28]. Chloasma mostly occurred in respondents 
who did not use sunscreen. Chloasma showed no correlation to the 
respondents’ daily activities (p=0.203) and sunscreen use (p=0.078). 
Chloasma in oral contraceptive users is caused by the steroid effects 
of melanogenesis in melanocytes [29]. An increase in EE is known to 
activate melanocytes and cause hyperpigmentation in the face [30]. 
The difference in the incidence rate of chloasma is assumed to be 
caused by the effects of combined progestin and EE. Progestin may 
inhibit EE induction of melanogenesis in melanocytes [30]. DSG as a 
third-generation progestin is assumed to have better inhibition effect 
(antiestrogenic) than LNG.
Analysis of ADR with oral contraceptive type
The results show a statistically significant difference in impaired sexual 
intercourse and face spots (p<0.05). Although it is proportionally 
different, breast tenderness could not be statistically analyzed further 
because its incidence in the EE-DSG group is zero. EE-LNG is 3.75 times 
more likely to cause impaired sexual intercourse and 7.51 times more 
likely to cause face spots compared to EE-DSG. In general, this study 
found that EE-LNG poses a higher risk of ADR than EE-DSG. This proves 
the hypotheses that third-generation progestin has lower ADR risks [4].
Theoretically, ADR can be influenced by the contraceptive type, duration 
of use, user age, user BMI, compliance, and other risk factors [14]. This 
study analyzed the effects of contraceptive type, user age, duration of 
use, and BMI on ADR. Bivariate analysis showed that age, duration of use, 
and BMI affected sexual intercourse and face spots without a significant 
difference between both groups. This study uses retrospective data 
obtained from an interview, and bias of memory recall may be present. 
The relations between ADR and user compliance as well as decision to 
continue using the contraceptive were not clarified. The correlation 
of ADR with compliance must be determined. Data in Indonesia show 
that ADR is the second most important reason for withdrawal from 
the use of contraceptives. Furthermore, enough users are still not 
given information about ADR [2]. Periodic observance and counseling 
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are needed to minimize withdrawal from the use of contraceptives. 
Pharmacies must play a role in this regard because most users obtain 
contraceptives from pharmacies.
CONCLUSION
The effect of ADR was higher in the EE-LNG group than in the EE-DSG 
group. The EE-LNG group showed a statistically significant difference 
for impaired sexual intercourse (OR: 3.75, 95% CI: 1.003-14.050, 
p=0.039) and chloasma (OR: 7.51, 95% CI: 1.629-34.647, p=0.004). 
Furthermore, 43% of users were not aware of ADR risks arising from 
oral contraceptives. Most users had previously withdrawn from the 
use of injection contraceptives because of ADR. Users’ low knowledge 
of ADR and how to treat it could be the reason for drug withdrawal. 
Pharmacies must make an effort to provide counseling in this regard.
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